TITLE

Nelfinavir/nevirapine/zidovudine withdrawal

PUB. DATE
May 2004
SOURCE
Reactions Weekly;5/1/2004, Issue 999, p12
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
Discuses research being done on the development of multiple organ failure in a woman patient receiving nelfinavir, nevirapine and zidovudine for HIV infection. Reference to a study by M. Crespo et al published in a January 2004 issue of the "European Journal of Clinical Microbiology and Infectious Diseases"; Symptoms exhibited by the patient; Significance of antiretroviral agents to the condition of the patient.
ACCESSION #
16065830

 

Related Articles

  • Vicriviroc.  // Reactions Weekly;8/11/2007, Issue 1164, p26 

    The article describes the case of a 52-year-old man with HIV infection who developed rhinocerebral zygomycosis during treatment with vicriviroc. It references a study by S. Merchant and colleagues published in the July 31, 2007 issue of the journal "AIDS." The patient started receiving...

  • Recurrent hypersensitivity to Combivir. Winston, Alan; McLean, Ken // International Journal of STD & AIDS;Mar2002, Vol. 13 Issue 3, p213 

    The non-nucleoside reverse transcriptase inhibitors (NNRTIs) are commonly used in combination antiretroviral therapy and are associated with hypersensitivity reactions on induction therapy. We report a case of recurrent hypersensitivity associated with Combivir, when there was a delay in...

  • Combination Therapy with Zidovudine and Dideoxycytidine in Patients with Advanced Human Immunodeficiency Virus Infection. Tze-Chiang Meng; Fischl, Margaret A.; Boota, Ahmad M.; Spector, Stephen A.; Bennett, Donnaie; Bassiakos, Yiannis; Shenghan Lai; Wright, Brian; Richman, Douglas D. // Annals of Internal Medicine;1/1/92, Vol. 116 Issue 1, p13 

    Evaluates the safety and effects of combination therapy with zidovudine and dideoxycytidine in patients with advanced HIV infection. Characteristics of the patients; Side effects of the combination therapy; Changes in the CD4 antigen.

  • Efavirenz/lamivudine/zidovudine.  // Reactions Weekly;8/15/2009, Issue 1265, p17 

    The article presents a case study of a 44-year-old man who developed immune reconstitution syndrome during treatment with efavirenz, lamiduvine and zidovudine for human-immunodeficiency virus (HIV) infection. The drugs were commenced and he was treated with amoxicillin/cluvanalic acid,...

  • Lamivudine/nelfinavir/zidovudine.  // Reactions Weekly;1/24/2009, Issue 1236, p24 

    The article describes the case of a 1-day-old girl who experienced necrotising enterocolitis after in utero and postdelivery exposure to antiretroviral therapy for maternal HIV infection. At 20 weeks gestation, the mother of the girl began receiving antiretroviral therapy with lamivudine,...

  • Zidovudine.  // Reactions Weekly;2/11/2006, Issue 1088, p22 

    This article presents a case report involving a male patient who developed ragged-red fiber myopathy during antiretroviral therapy with zidovudine for HIV infection. It provides a background on the medical history of the patient. It describes the symptoms presented by the patient. It offers...

  • Structured Intermittent Therapy with Seven-Day Cycles of HAART for Chronic HIV Infection: A Pilot Study in São Paulo, Brazil. Casseb, Jorge; Da Silva Duarte, Alberto Jos // AIDS Patient Care & STDs;Jul2005, Vol. 19 Issue 7, p425 

    In the last 6 years, an impressive impact of the highly active antiretroviral therapy (HAART) on survival and morbidity in HIV-1–infected individuals has been attained. However, their prolonged use may induce metabolic adverse effects such as lipodistrophy, hypertension, diabetes...

  • More new non-AIDS illnesses with Epzicom than Truvada in 96-week trial.  // HIV Treatment ALERTS!;Apr2010, p3 

    The article presents a study on the association of non-AIDS illnesses with the use of Epzicom and Truvada. It says that a trial called Simplification with Tenofovir-Emtricitabine or Abacavir-Lamiduvine (STEAL) was performed on 357 adults within a 96-week trial. Results reveal that people taking...

  • Skip HIV therapy.  // New Scientist;8/12/2006, Vol. 191 Issue 2564, p7 

    The article focuses on research by Bernard Hirschel at the University Hospital of Geneva in Switzerland and his colleagues which revealed that people who take closely monitored breaks from highly active anti-retroviral therapy for HIV infection might also suffer fewer side effects. There are...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics